Decoy Therapeutics Inc.
DCOYHealthcare|Biotechnology|US
$1.13
+0.01 (+0.88%)
DCF Value
$20.42
Tangible Book / Share
$8.12
Cash / Share
$15.58
About
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Stock Price
-96.7%(1Y)
1M
-25.7%
3M
-71.2%
6M
-80.2%
YTD
-85.5%
1Y
-95.3%
3Y
-99.9%
5Y
-100.0%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$601.1K
Employees11 (+450% YoY)
CEOFrederick E. Pierce
IPO DateJan 29, 2015
Beta0.58
52-Week Range$0.9 – $38.4
Avg Volume1,705,418
ExchangeNASDAQ
Websitedecoytx.com
Ownership
Float99.4%
Shares Outstanding0.5M
Recent Insider Trades
Lieber Jonathan IAWARD
Aug 31, 20262,000 shares
PIERCE FREDERICK IIAWARD
Aug 31, 202633,455 shares
Marschel Peter KlausAWARD
Aug 31, 20263,900 shares
Rosenblum Mark JAWARD
Aug 31, 20269,682 shares
Hibner Barbara LouiseAWARD
Aug 31, 20264,216 shares
Peers
Recent News
Decoy Therapeutics Provides Third Quarter 2026 Business Update
Nov 3, 2026 · globenewswire.com
Decoy Therapeutics to Present at The Small Cap Showcase
Sep 30, 2026 · globenewswire.com
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
Sep 29, 2026 · prnewswire.com
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
Sep 22, 2026 · prnewswire.com
Data last updated: Nov 9, 2026, 04:06 AM